BASKING RIDGE, N.J., March 2 /PRNewswire-FirstCall/ -- VioQuest Pharmaceuticals, Inc. , a New Jersey-based biopharmaceutical company focused on acquiring, developing and commercializing targeted cancer compounds, is participating in a series of live interviews on “Steve Crowley’s American Scene” national financial talk-radio program. Daniel Greenleaf, VioQuest Pharmaceuticals’ President and CEO, began the interview series in mid-February and will continue through June 2007.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGO )
Mr. Greenleaf will discuss various aspects of VioQuest’s business strategy, its targeted cancer therapeutics approach, and the clinical trials for its two targeted cancer agents, VQD-001, currently in Phase I/IIa clinical trials for solid tumors, and VQD-002 in Phase I/IIa clinical trials for leukemia and solid tumors. Additionally, Mr. Greenleaf will discuss the upcoming NDA filing for leishmaniasis for VQD-001.
About “Steve Crowley’s American Scene”
The daily “Investors Showcase” segment of “Steve Crowley’s American Scene” radio program, syndicated nationally by the Business Talk Radio Network, will now be featuring VioQuest Pharmaceuticals, Inc. on its program. Steve Crowley’s American Scene (http://www.americansceneradio.com) is broadcast for three hours every weekday between the hours of 9 a.m. and 12 a.m. Eastern time and 6 a.m. and 9 a.m. Pacific. It airs in major markets including New York, Washington DC, Chicago, Minneapolis, Los Angeles, San Diego, Portland, St. Louis, Atlanta, South Florida, Orlando and many other cities nationally.
This financial talk radio program was launched in June 1990, and is hosted by Steve Crowley, the former Money Editor of ABC’s “Good Morning America” and author of Money For Life, published by Simon & Schuster.
About VioQuest Pharmaceuticals
VioQuest Pharmaceuticals, Inc. www.vioquestpharm.com focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. VioQuest has two targeted therapeutics in Phase I/IIa clinic trials: VQD-002 which appears to inhibit phosphorylation of Akt that is seen at abnormally high levels in breast, ovarian, colorectal, pancreatic, and hematologic tumors; and VQD-001, an inhibitor of specific protein tyrosine phosphatases, which has shown compelling preclinical activity in both renal and melanoma cancers. In addition, VioQuest and the U.S. Army are planning to submit an NDA to the FDA in 2007 for VQD-001 for the treatment of leishmaniasis. VioQuest’s subsidiary Chiral Quest, Inc., a pioneer in asymmetric chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug. VioQuest is seeking strategic alternatives for Chiral Quest, which may include its sale.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest’s actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that the FDA will approve VioQuest’s planned NDA submission relating to VQD-001 for the treatment of leishmaniasis, and even if approved, there is no assurance that VioQuest will be able to successfully commercialize VQD-001 for the treatment of leishmaniasis or any other indication. Further, there us no assurance that VioQuest will receive any proceeds in connection with a sale or other disposition of its Chiral Quest division. Other risks and uncertainties include the possibility that its planned and ongoing clinical trials will not be initiated or completed as anticipated, that the results of clinical trials will not support VioQuest’s claims, the possibility that VioQuest’s development efforts relating to its product candidates, including VQD-001 and VQD-002, will not be successful, the inability to obtain regulatory approval of VioQuest’s product candidates, VioQuest’s reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest’s Annual Report on Form 10-KSB for the year ended December 31, 2005. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Photo: http://www.newscom.com/cgi-bin/prnh/20070117/NYW085LOGOVioQuest Pharmaceuticals, Inc.
CONTACT: Daniel Greenleaf, President and Chief Executive Officer, +1-908-766-4400, ext. 115, dan.greenleaf@vioquestpharm.com; Brian Lenz, ChiefFinancial Officer, +1-908-766-4400, ext. 117, brian.lenz@vioquestpharm.com;Diane Perry, VP, Investor Relations & Corporate Communications, +1-917-834-7526, +1-908-766-4400, ext. 116, diane.perry@vioquestpharm.com
